PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. Co. develops, manufactures and sells the AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). BPH is a common prostate disease. The AquaBeam Robotic System employs a single-use disposable handpiece to deliver Co.'s proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted removal of prostate tissue. The PRCT average annual return since 2021 is shown above.
The Average Annual Return on the PRCT average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PRCT average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PRCT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|